Advaxis Company Profile (NASDAQ:ADXS)

About Advaxis (NASDAQ:ADXS)

Advaxis logoAdvaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADXS
  • CUSIP: N/A
  • Web: www.advaxis.com
Capitalization:
  • Market Cap: $339.69 million
  • Outstanding Shares: 40,295,000
Average Prices:
  • 50 Day Moving Avg: $8.27
  • 200 Day Moving Avg: $8.56
  • 52 Week Range: $6.97 - $16.30
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.19
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $7.54 million
  • Price / Sales: 45.05
  • Book Value: $2.67 per share
  • Price / Book: 3.16
Profitability:
  • EBIDTA: ($73,060,000.00)
  • Return on Equity: -72.97%
  • Return on Assets: -61.65%
Debt:
  • Current Ratio: 5.77%
  • Quick Ratio: 5.77%
Misc:
  • Average Volume: 584,548 shs.
  • Beta: 2.13
  • Short Ratio: 12.06
 

Frequently Asked Questions for Advaxis (NASDAQ:ADXS)

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) posted its quarterly earnings results on Friday, March, 10th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.09. The firm earned $3.79 million during the quarter, compared to analyst estimates of $2.15 million. View Advaxis' Earnings History.

Where is Advaxis' stock going? Where will Advaxis' stock price be in 2017?

5 analysts have issued 1-year price objectives for Advaxis' shares. Their forecasts range from $19.00 to $34.00. On average, they expect Advaxis' stock price to reach $24.00 in the next year. View Analyst Ratings for Advaxis.

Who are some of Advaxis' key competitors?

Who owns Advaxis stock?

Advaxis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (0.00%), Vanguard Group Inc. (0.00%), Broadfin Capital LLC (3.77%), Sarissa Capital Management LP (0.84%), MARSHALL WACE ASIA Ltd (0.00%) and Marshall Wace North America L.P. (0.00%). Company insiders that own Advaxis stock include Adage Capital Partners Gp Llc, Daniel O'connor, David J Mauro, David Sidransky, Gregory T Mayes, Richard J Berman, Robert Petit, Sara Bonstein and Thomas J Mckearn. View Institutional Ownership Trends for Advaxis.

Who sold Advaxis stock? Who is selling Advaxis stock?

Advaxis' stock was sold by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, Credit Suisse AG, Nexthera Capital LP, Morgan Stanley, TIAA CREF Investment Management LLC, Alliancebernstein L.P., Tocqueville Asset Management L.P. and Nationwide Fund Advisors. Company insiders that have sold Advaxis stock in the last year include Daniel O'connor, David Sidransky, Gregory T Mayes, Richard J Berman, Robert Petit, Sara Bonstein and Thomas J Mckearn. View Insider Buying and Selling for Advaxis.

Who bought Advaxis stock? Who is buying Advaxis stock?

Advaxis' stock was bought by a variety of institutional investors in the last quarter, including MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., FMR LLC, Vanguard Group Inc., Parametric Portfolio Associates LLC, Bank of Montreal Can, Tudor Investment Corp ET AL and Vident Investment Advisory LLC. Company insiders that have bought Advaxis stock in the last two years include Adage Capital Partners Gp Llc and Richard J Berman. View Insider Buying and Selling for Advaxis.

How do I buy Advaxis stock?

Shares of Advaxis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Advaxis stock cost?

One share of Advaxis stock can currently be purchased for approximately $8.43.

Analyst Ratings

Consensus Ratings for Advaxis (NASDAQ:ADXS) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.00 (184.70% upside)

Analysts' Ratings History for Advaxis (NASDAQ:ADXS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/13/2017HC WainwrightSet Price TargetBuy$23.00LowView Rating Details
2/27/2017Cantor FitzgeraldReiterated RatingBuy$19.00N/AView Rating Details
9/9/2016Jefferies Group LLCReiterated RatingBuy$24.00N/AView Rating Details
8/3/2016Barclays PLCBoost Price TargetOverweight$15.00 -> $20.00N/AView Rating Details
7/7/2016FBR & CoReiterated RatingOutperform$34.00N/AView Rating Details
12/17/2015Janney Montgomery ScottReiterated RatingBuy$22.00N/AView Rating Details
9/11/2015GuggenheimInitiated CoverageBuy$30.00N/AView Rating Details
6/26/2015MLV & Co.Initiated CoverageBuyN/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Advaxis (NASDAQ:ADXS)
Earnings by Quarter for Advaxis (NASDAQ:ADXS)
Earnings History by Quarter for Advaxis (NASDAQ:ADXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/10/2017Q1 2017($0.52)($0.43)$2.15 million$3.79 millionViewN/AView Earnings Details
6/8/2016Q2 2016($0.54)($0.45)$0.13 millionViewN/AView Earnings Details
3/13/2015Q1 2015($0.31)($0.33)ViewN/AView Earnings Details
6/9/2014Q3 2014($0.25)($0.30)$1.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Advaxis (NASDAQ:ADXS)
2017 EPS Consensus Estimate: ($2.20)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.51)($0.51)($0.51)
Q2 20171($0.54)($0.54)($0.54)
Q3 20171($0.56)($0.56)($0.56)
Q4 20171($0.59)($0.59)($0.59)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Advaxis (NASDAQ:ADXS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Advaxis (NASDAQ:ADXS)
Insider Ownership Percentage: 4.56%
Institutional Ownership Percentage: 57.42%
Insider Trades by Quarter for Advaxis (NASDAQ:ADXS)
Institutional Ownership by Quarter for Advaxis (NASDAQ:ADXS)
Insider Trades by Quarter for Advaxis (NASDAQ:ADXS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/31/2017Robert PetitInsiderSell2,454$8.24$20,220.96View SEC Filing  
12/30/2016Sara BonsteinCFOSell5,520$7.37$40,682.40View SEC Filing  
12/20/2016Thomas J MckearnDirectorSell12,316$8.08$99,513.28View SEC Filing  
11/2/2016Daniel O'connorCEOSell8,240$8.32$68,556.80View SEC Filing  
11/2/2016Robert PetitInsiderSell2,797$8.32$23,271.04View SEC Filing  
10/25/2016Gregory T MayesInsiderSell19,162$8.23$157,703.26View SEC Filing  
8/9/2016David SidranskyDirectorSell22,808$15.01$342,348.08View SEC Filing  
8/8/2016Richard J BermanDirectorSell18,000$15.21$273,780.00View SEC Filing  
5/13/2016Thomas J MckearnDirectorSell4,100$7.45$30,545.00View SEC Filing  
5/2/2016Daniel O'connorCEOSell8,237$7.51$61,859.87View SEC Filing  
5/2/2016Robert PetitInsiderSell2,785$7.51$20,915.35View SEC Filing  
3/31/2016Robert PetitInsiderSell3,325$9.13$30,357.25View SEC Filing  
3/16/2016Thomas J MckearnDirectorSell14,000$8.25$115,500.00View SEC Filing  
2/24/2016Sara BonsteinCFOSell15,037$5.58$83,906.46View SEC Filing  
1/29/2016Daniel O'connorCEOSell8,818$6.88$60,667.84View SEC Filing  
1/29/2016Robert PetitinsiderSell3,099$6.88$21,321.12View SEC Filing  
10/26/2015Gregory T MayesCOOSell19,231$11.63$223,656.53View SEC Filing  
10/20/2015David J MauroInsiderSell24,586$10.08$247,826.88View SEC Filing  
8/24/2015Adage Capital Partners Gp LlcMajor ShareholderBuy300,000$14.15$4,245,000.00View SEC Filing  
4/30/2015Adage Capital Partners Gp LlcMajor ShareholderBuy500,000$19.00$9,500,000.00View SEC Filing  
2/18/2015Adage Capital Partners Gp LlcMajor ShareholderBuy684,762$7.50$5,135,715.00View SEC Filing  
5/9/2014Richard J BermanDirectorSell14,530$2.63$38,213.90View SEC Filing  
3/31/2014Daniel O'connorCEOBuy3,333$3.00$9,999.00View SEC Filing  
10/24/2013Daniel O'connorCEOBuy13,500$4.00$54,000.00View SEC Filing  
10/24/2013Mark J RosenblumCFOBuy12,000$4.00$48,000.00View SEC Filing  
10/24/2013Robert PetitInsiderBuy12,800$4.00$51,200.00View SEC Filing  
10/24/2013Roni AppelDirectorBuy12,500$4.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Advaxis (NASDAQ:ADXS)
Latest Headlines for Advaxis (NASDAQ:ADXS)
Source:
DateHeadline
seekingalpha.com logo3 Things In Biotech You Should Learn Today: May 18, 2017
seekingalpha.com - May 18 at 12:25 PM
finance.yahoo.com logoAdvaxis to Host Investor & Analyst Day on June 12
finance.yahoo.com - May 18 at 12:25 PM
finance.yahoo.com logoAdvaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : May 15, 2017
finance.yahoo.com - May 16 at 8:21 PM
businesswire.com logoAdvaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac - Business Wire (press release)
www.businesswire.com - May 15 at 3:22 PM
finance.yahoo.com logoErin Andrews to Participate in Cervical Cancer Educational Forum Hosted by Sylvester Comprehensive Cancer Center and Gilda’s Club, Sponsored by Advaxis
finance.yahoo.com - May 5 at 3:22 PM
finance.yahoo.com logoETFs with exposure to Advaxis, Inc. : May 4, 2017
finance.yahoo.com - May 4 at 8:24 PM
americanbankingnews.com logoAdvaxis (ADXS) Receiving Positive Media Coverage, Study Shows
www.americanbankingnews.com - May 3 at 8:34 AM
finance.yahoo.com logoAdvaxis, Inc. – Value Analysis (NASDAQ:ADXS) : April 28, 2017
finance.yahoo.com - April 28 at 8:50 PM
thestreet.com logoCommit To Buy Advaxis At $7.50, Earn 16.4% Annualized Using Options - TheStreet.com
www.thestreet.com - April 27 at 8:44 PM
finance.yahoo.com logoAdvaxis Recognized as One of New Jersey’s “Best Places to Work 2017”
finance.yahoo.com - April 27 at 11:45 AM
finance.yahoo.com logoAdvaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : April 27, 2017
finance.yahoo.com - April 27 at 11:44 AM
americanbankingnews.com logoAdvaxis (ADXS) Earning Somewhat Positive News Coverage, Report Finds
www.americanbankingnews.com - April 25 at 2:24 PM
nasdaq.com logoMagee Thomson Investment Partners Llc Buys Inphi, Take-Two Interactive Software, Domino's ...
www.nasdaq.com - April 22 at 3:19 PM
finance.yahoo.com logoETFs with exposure to Advaxis, Inc. : April 21, 2017
finance.yahoo.com - April 21 at 3:22 PM
americanbankingnews.com logoFavorable News Coverage Very Likely to Impact Advaxis (ADXS) Share Price
www.americanbankingnews.com - April 20 at 10:43 AM
globenewswire.com logoAdvaxis Appoints Anthony Lombardo as Chief Business Officer - GlobeNewswire (press release)
globenewswire.com - April 19 at 3:19 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Somewhat Likely to Impact Advaxis (ADXS) Share Price
www.americanbankingnews.com - April 14 at 3:50 PM
americanbankingnews.com logoShort Interest in Advaxis, Inc. (ADXS) Rises By 3.7%
www.americanbankingnews.com - April 6 at 1:28 PM
americanbankingnews.com logoAdvaxis, Inc. (ADXS) Insider Robert Petit Sells 2,454 Shares
www.americanbankingnews.com - April 3 at 8:28 PM
seekingalpha.com logoInvesting In Advaxis: Biotech Gold Or Bust
seekingalpha.com - March 31 at 3:26 PM
us.rd.yahoo.com logoAdvaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac
us.rd.yahoo.com - March 28 at 7:50 AM
globenewswire.com logoAdvaxis Provides Phase 1 Data of Higher Dose Axalimogene ... - GlobeNewswire (press release)
globenewswire.com - March 27 at 3:29 PM
investopedia.com logoEMA Certification Paves Way for Advaxis Drug (ADXS)
www.investopedia.com - March 23 at 11:35 PM
us.rd.yahoo.com logoEMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer
us.rd.yahoo.com - March 23 at 11:35 PM
seekingalpha.com logoAbout: Advaxis Inc. (ADXS) - Seeking Alpha
seekingalpha.com - March 23 at 3:32 PM
investopedia.com logoEMA Certification Paves Way for Advaxis Drug
www.investopedia.com - March 23 at 3:32 PM
finance.yahoo.com logoADVAXIS, INC. Financials
finance.yahoo.com - March 16 at 4:51 PM
us.rd.yahoo.com logoAdvaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO’s Annual Meeting on Women’s Cancer
us.rd.yahoo.com - March 15 at 8:27 PM
streetinsider.com logoAdvaxis (ADXS) Presents Oral Late-breaking Data on Phase 2 GOG ... - StreetInsider.com
www.streetinsider.com - March 15 at 3:24 PM
globenewswire.com logoAdvaxis to Present at the 2017 Barclays Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 14 at 8:18 AM
americanbankingnews.com logoAdvaxis, Inc. (ADXS) PT Set at $23.00 by HC Wainwright
www.americanbankingnews.com - March 13 at 4:28 PM
finance.yahoo.com logoAdvaxis to Present at the 2017 Barclays Global Healthcare Conference
finance.yahoo.com - March 13 at 3:22 PM
finance.yahoo.com logoAdvaxis Appoints Al Blunt, M.D., as its Vice President of Medical
finance.yahoo.com - March 7 at 3:21 PM
streetinsider.com logoAdvaxis (ADXS) IND for ADXS-NEO Accepted by FDA - StreetInsider.com
www.streetinsider.com - March 7 at 6:04 AM
us.rd.yahoo.com logoAdvaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO
us.rd.yahoo.com - March 6 at 11:23 AM
us.rd.yahoo.com logo6:01 am Advaxis announces FDA acceptance of IND for personalized neoepitope immunotherapy, ADXS-NEO
us.rd.yahoo.com - March 6 at 11:23 AM
us.rd.yahoo.com logoAdvaxis to Host Research Reception at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer
us.rd.yahoo.com - March 2 at 8:33 PM
nasdaq.com logoAdvaxis to Host Research Reception at Society of Gynecologic ... - Nasdaq
www.nasdaq.com - March 2 at 3:31 PM
streetinsider.com logoAdvaxis (ADXS), SELLAS Enter Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy
www.streetinsider.com - February 28 at 3:23 PM
investopedia.com logoAdvaxis Inks Cancer Drug Deal with Sellas (ADXS)
www.investopedia.com - February 28 at 3:23 PM
investopedia.com logoAdvaxis Inks Cancer Drug Deal with Sellas
www.investopedia.com - February 28 at 3:23 PM
finance.yahoo.com logoAdvaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy
finance.yahoo.com - February 27 at 3:29 PM
finance.yahoo.com logo8:04 am Advaxis and Sellas Life Sciences announce licensing agreement for development of wt1 antigen-targeting immunotherapy
finance.yahoo.com - February 27 at 3:29 PM

Social

Chart

Advaxis (ADXS) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff